With innovative advancements in science & technology, cancer treatment has dramatically improved by discovering molecular targeted agents. However, identifying eligible patients and predicting their therapeutic effects still remain a great challenge. Because genetic and molecular differences of tumors significantly affect therapeutic effects in clinical, establishing individualized medicine based on precise molecular pathogenesis is urgently required.
Cylindromatosis (CYLD) was originally identified as a tumor suppressor because loss of which causes a benign human tumor called cylindromatosis. Increasing clinical evidence reveals that dysfunction of CYLD by loss of its expression is believed to play key roles in diverse pathological processes in various types of tumors. Moreover, our results have shown that loss of CYLD expression not only be involved in tumor malignant transformation, but also serves as a prognostic & predictive biomarker for several tumors.
In this session, we focus on the clinical significance of CYLD and introduce our approaches toward developing a novel molecular targeted therapies. Deeper understanding of more biological feature and clinical significance of CYLD may open up novel strategies for establishing individualized cancer treatment for malignant tumors.